Long-acting solid formulation comprising triptorelin acetate
The invention relates to a long-acting solid formulation for parenteral administration, comprising a) triptorelin acetate and b) one or more excipients comprising a polymer or copolymer of lactic and/or glycolic acid or a mixture of polymers and/or copolymers of lactic acid and/or glycolic acid, said formulation containing 10 to 99% of triptorelin acetate by weight with relation to the total weight of the formulation. Said formulation is obtained by means of a method comprising the fusion of a mixture of triptorelin acetate and the excipient(s) on the fusion/extrusion of the triptorelin acetate with the excipient(s), said formulation being embodied such as to release the triptorelin acetate over a duration of at least one week, once administered parenterally to a patient.
1 . Solid sustained-release formulation for parenteral administration comprising:
a) triptorelin acetate, and
b) one or more excipient(s) comprising a lactic acid and/or glycolic acid polymer or copolymer or a mixture of lactic acid and/or glycolic acid polymers and/or copolymers, said formulation including 10 to 99% triptorelin acetate by weight relative to the total weight of the formulation, wherein said formulation is obtained by a process comprising the melting of the mixture of triptorelin acetate and excipient or excipients during the melting-extrusion of triptorelin acetate with the excipient or excipients, and wherein
said formulation releases the triptorelin acetate over a period of at least one week once administered to a patient by parenteral route.
2 . Sustained-release formulation according to claim 1 , wherein said formulation releases the triptorelin acetate in an effective dose for a period of at least 14 days.
3 . Sustained-release formulation according to claim 1 , wherein said formulation releases the triptorelin acetate in an effective dose for a period of at least 28 days.
4 . Sustained-release formulation according to claim 1 , wherein said formulation releases the triptorelin acetate in an effective dose for a period of at least 90 days.
5 . Sustained-release formulation according to claim 1 , wherein said formulation comprises 20 to 90% by weight of triptorelin acetate relative to the total weight of the formulation.
6 . Sustained-release formulation according to claim 1 , wherein said formulation comprises 30 to 70% by weight of triptorelin acetate relative to the total weight of the formulation.
7 . Sustained-release formulation according to claim 1 , wherein said lactic acid and/or glycolic acid polymer or copolymer or the mixture of lactic acid and/or glycolic acid polymers and/or copolymers is a lactic acid and glycolic acid copolymer or a mixture of such copolymers.
8 . Sustained-release formulation according to claim 7 , wherein said lactic acid and glycolic acid copolymer or copolymers are copolymers comprising 50% to 85% units derived from lactic acid and 15% to 50% units derived from glycolic acid.
9 . Sustained-release formulation according claim 1 , wherein said formulation comprises more than 35% triptorelin acetate by weight relative to the total weight of the formulation and wherein the mixture of triptorelin acetate with the polymer or copolymer excipient or excipients has been dried before the melting-extrusion so that its water content does not exceed 8% by weight.
10 . Sustained-release formulation according to claim 9 , wherein the mixture of triptorelin acetate with the polymer or copolymer excipient or excipients has been dried before the melting-extrusion so that its water content does not exceed 4% by weight.
11 . A solid sustained-release formulation for parenteral administration comprising a melt-extruded mixture of:
a) triptorelin acetate, and
b) one or more excipient(s) comprising a lactic acid and/or glycolic acid polymer or copolymer or a mixture of lactic acid and/or glycolic acid polymers and/or copolymers,
said formulation including 10 to 99% triptorelin acetate by weight relative to the total weight of the formulation, and wherein said formulation exhibits at least one of: a sustained release of an effective dose of triptorelin acetate for a period of at least one week or a reduction in release burst of triptorelin acetate compared to standard formulations when administered to a patient by parenteral route.